C2N Diagnostics

C2N Diagnostics announces a $10 million investment from Samsung C&T Corporation, Samsung Biologics, Samsung Bioepis and Samsung Venture Investment Corporation (collectively hereinafter referred to as “Samsung”). C2N says Samsung’s decision bolsters its ability to further scale its clinical laboratory services and advanced diagnostic solutions in the field of brain health. Jaywoo Kim, Executive Vice President of Samsung C&T Corporation, says, “Since Samsung C&T stepped into the life sciences industry by investing in biologics CDMO and biosimilar business, it has contributed to the stabilization of the biopharmaceutical supply chain and better access to high quality bio pharmaceutics. The investment into C2N Diagnostics shows Samsung’s continued dedication to future growth in the Life Science sector by seeking new business opportunities based on intelligent analytics and uniquely special diagnostics technologies. We are confident that C2N Diagnostics will further grow its leading position in the industry by serving global biopharma customers as well as medical service providers with its well-established blood biomarker testing portfolio.” https://lnkd.in/erb9KsmJ #Samsung #SamsungCTCorporation #investment #clinicallabservices #lifesciences #bloodbiomarker #brainhealth

Joel Braunstein, MD, CEO of C2N Diagnostics, will chair a meeting session and also speak Wednesday, March 11, at Precision Med TRI-CON; the conference “has served as the leading international meeting place for the diagnostics and precision medicine community.”   He’ll discuss “The Emergence of High-Performance Blood Biomarkers to Transform Clinical Diagnosis in Alzheimer’s Disease: Lessons from the PrecivityAD2 Blood Test.”   The conference session is titled “Precision Medicine Beyond Oncology: Diagnostics and Personalized Medicine in Immunology, Neurology, and Metabolic Diseases,” and it opens at 2 p.m. PT.   Dr. Braunstein will provide the opening session remarks and will present his topic at 2:35 p.m. PT on March 11. https://lnkd.in/gnkFYWex   #PrecisionMedTRICON #TriConference #TRICON #clinicaldiagnosis #precisionmedicine  

Joel Braunstein, MD speaks at the Global Alzheimer’s Platform Foundation Site Optimization Conference 2025 panel session titled: “Optimizing Health Systems: Leveraging Blood Biomarkers & Digital Assessments for Enhanced Referrals & Trials." Dr. Braunstein discussed the critical work in the standardization of blood biomarker tests in health systems, how to optimize their quality for the benefit of patient care, and the nuances of various federal and state requirements for Laboratory Developed Tests (LDTs). #GAPFoundation #precisionmedicine #Alzheimers #Alzheimersdisease #bloodbiomarkers

National Library of Medicine (NLM) MedlinePlus website has complete details about caregiving for a patient with Alzheimer’s disease. There’s information about how a caregiver needs to look after him or herself, how to get legal and financial affairs in order, and links to local resources. Click here: https://lnkd.in/eQRsr3iY #NationalLibraryofMedicine #Alzheimers #AlzheimersDisease #caregiver #MedlinePlus #advice 

C2N Diagnostics, a pioneer in advanced diagnostic testing for brain health, today announced United Kingdom healthcare providers can now access the uniquely differentiated PrecivityAD2™ blood test to aid in diagnosing Alzheimer’s disease.   C2N has received medical device certification for the PrecivityAD2 blood test for in vitro diagnostics use from UK’s Medicines and Healthcare products Regulatory Agency (MHRA).   https://lnkd.in/e4NRiXRx #UnitedKingdom #Alzheimersdisease #dementia #UK #England #UKhealth #EnglishHealthNews #UKpatients #MedicinesandHealthcareproductsRegulatoryAgency #MHRA

C2N is excited to be part of the Pri-Med South conference from February 6-8 in Ft. Lauderdale. Organizers say it’s an opportunity for expert faculty to “provide the latest primary care updates and keynote addresses.” C2N will be at booth #316, where we’ll be sharing details about the Precivity™ tests, which are innovative new blood tests intended for use in patients 55 and older with signs or symptoms of mild cognitive impairment or dementia. These tests aid healthcare providers in the detection of amyloid plaques in the brain, a pathological hallmark of Alzheimer's disease, and inform medical management and treatment decisions. https://lnkd.in/ekdF2Ujb #PriMedSouth #bloodbiomarkers #AlzheimersDisease #medicalconference #dementia

Recently published research speaks to the need to find more accessible and less invasive ways to help healthcare providers make an Alzheimer’s disease diagnosis. The study, appearing in the journal Nature Medicine, reports that new cases of dementia in the United States are projected to double in the next three decades. The study also showed that the risk of developing dementia after age 55 is 42%, more than double the risk seen by older studies. After age 75, the lifetime risk increases to more than 50%, according to the study. C2N’s Precivity™ tests are innovative new blood tests intended for use in patients 55 and older with signs or symptoms of mild cognitive impairment or dementia. These tests aid healthcare providers in the detection of amyloid plaques in the brain, a pathological hallmark of Alzheimer's disease, and inform medical management and treatment decisions. The Precivity blood tests for assessment of brain amyloid pathology offer an accessible and less procedurally complex testing option for healthcare providers and patients compared to amyloid PET scan or CSF testing. https://lnkd.in/ggvW4tNg www.precivityAD.com #NatureMedicine #dementia #AlzheimersDisease #risks #aging #research #amyloidpathology

Study finds C2N’s PrecivityAD2™ Blood Test Improves Clinical Decision-Making in the Evaluation for Alzheimer’s Disease The peer-reviewed Diagnostics Journal published Clinical Utility of an Alzheimer’s Disease Blood Test Among Cognitively Impaired Patients: Results from the Quality Improvement PrecivityAD2 (QUIP II) Clinician Survey Study. Study researchers have determined that use of PrecivityAD2 blood test, which determines presence or absence of amyloid plaques in the brain, increased their ability to make Alzheimer’s disease (AD) probability judgments on their patients. This change in clinician-reported probability of AD is also associated with meaningful improvements in downstream clinical care, including changes in plans for AD medications as well as additional brain amyloid testing. https://lnkd.in/ep3hGNTb #Diagnostics #medicaljournal #Alzheimersdisease #bloodtest #dementia #bloodbiomarker #precisionmedicine #Alzheimers #brainamyloid

C2N CEO Joel Braunstein, MD will be presenting at the NeuroNet 2025 Annual Summit in Nashville. The title of his talk is “Transforming Alzheimer’s Disease Diagnosis with the PrecivityAD2™ Blood Test: Seeking to Establish a New Clinical Care Standard for Patients with Memory Impairment.” Dr. Braunstein and C2N staff will be in the product theater on Level 4 - Room North Coast on Friday, January 31, from 10:30 - 11:30 a.m. C2N’s PrecivityAD2 blood test gives healthcare providers a clear picture of Alzheimer’s disease pathology. More details are available at https://lnkd.in/efGXMqMY Learn more about the summit at https://lnkd.in/e3NSHXbv #NeuroNet #NeuroNet2025 #neurology #Alzheimer’sDisease #bloodbiomarker #bloodtest #clinicalcare

C2N Diagnostics is proud to announce that the Toronto Memory Program (TMP) is the first clinic in Canada to offer the PrecivityAD2™ blood test that healthcare providers use to help diagnose Alzheimer’s disease. This blood test allows healthcare providers to determine the presence or absence of amyloid pathology, a known hallmark of Alzheimer’s disease, through a simple, non-invasive approach. Other Canadian clinics are expected to soon join TMP in making the test available. Dr. Sharon Cohen, Behavioural Neurologist and Medical Director of TMP, says, “For far too long, early and accurate diagnosis of Alzheimer’s disease has been inaccessible to most Canadians due to reliance on expensive PET scans or lumbar punctures. This situation is untenable as emerging Alzheimer’s treatments require early diagnosis and biological confirmation. We are excited to offer our patients the option of C2N’s PrecivityAD2 as this easily accessible and highly accurate blood test helps us to determine whether Alzheimer’s disease is present in the brain, and to treat accordingly.” https://lnkd.in/e444yzEN #Canada #Toronto #Alzheimersdisease #bloodtest #dementia #bloodbiomarker #precisionmedicine #Alzheimers